Efficacy of liposomal amphotericin B and posaconazole in intratracheal models of murine mucormycosis

G Luo, T Gebremariam, H Lee, SW French… - Antimicrobial agents …, 2013 - Am Soc Microbiol
G Luo, T Gebremariam, H Lee, SW French, NP Wiederhold, TF Patterson, SG Filler
Antimicrobial agents and chemotherapy, 2013Am Soc Microbiol
Mucormycosis is a life-threatening fungal infection almost uniformly affecting diabetics in
ketoacidosis or other forms of acidosis and/or immunocompromised patients. Inhalation of
Mucorales spores provides the most common natural route of entry into the host. In this
study, we developed an intratracheal instillation model of pulmonary mucormycosis that
hematogenously disseminates into other organs using diabetic ketoacidotic (DKA) or
cyclophosphamide-cortisone acetate-treated mice. Various degrees of lethality were …
Abstract
Mucormycosis is a life-threatening fungal infection almost uniformly affecting diabetics in ketoacidosis or other forms of acidosis and/or immunocompromised patients. Inhalation of Mucorales spores provides the most common natural route of entry into the host. In this study, we developed an intratracheal instillation model of pulmonary mucormycosis that hematogenously disseminates into other organs using diabetic ketoacidotic (DKA) or cyclophosphamide-cortisone acetate-treated mice. Various degrees of lethality were achieved for the DKA or cyclophosphamide-cortisone acetate-treated mice when infected with different clinical isolates of Mucorales. In both DKA and cyclophosphamide-cortisone acetate models, liposomal amphotericin B (LAmB) or posaconazole (POS) treatments were effective in improving survival, reducing lungs and brain fungal burdens, and histologically resolving the infection compared with placebo. These models can be used to study mechanisms of infection, develop immunotherapeutic strategies, and evaluate drug efficacies against life-threatening Mucorales infections.
American Society for Microbiology